TheStreet: Alkermes should stick to drug delivery

Alkermes ($ALKS) is among the industry's most successful drug delivery firms, boasting licensing deals and royalty streams with drugmakers around the world, in addition to a few in-house treatments in the pipeline. Why, then, has its stock price stayed largely flat? In TheStreet, Nathan Sadeghi-Nejad writes that the company needs to build on its success in drug delivery, perhaps through timely acquisitions of smaller firms. Analysis

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.